Novo Nordisk is the second drug company to lower the price of insulin

Danish pharmaceutical company Novo Nordisk has announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with Type 1 and type 2 diabetes.  It becomes the second drugmaker to do so, following Eli Lilly's announcement earlier this month that it was capping out-of-pocket costs to $35 a month for insulin.

Read the full post at News Feed
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive